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Explaining the effects of the antithyroid hormone on the thyroid gland, 
converting it to thyroxine, then converting to triiodothyronine. 
(Laurberg and Cooper, 73). 
Case Study 
Large amounts of Americans are 
experiencing symptoms of thyroid 
dysfunction and go undiagnosed.  
The symptoms are what can be 
attributed to stress of everyday life.  
Once diagnosed, individuals are 
often unaware of the harmful effects 
of anti-thyroid drug therapy.  
Although rare, agranulocytosis is a 
harmful side effect, which can lead 
to series infections and even death. 
By making patients aware of the 
adverse affects and monitoring 
blood counts, the occurrence can 
continue to be low.   
A 32-year-old female presenting to the unit 
with a history of Graves’ disease.  Presenting 
symptoms included: fever, tonsil enlargement 
with noted white secretions, thyroid 
enlargement, and anemia.  Patient has been 
prescribed 15 mg of methamazole, which she 
had been taking for 42 days. Diagnostic 
testing shows a throat culture with moderate 
G- bacilli and G+ cocci. Patient was then 
treated with broad-spectrum antibiotics, 
vancomycin, cefoperazone sodium, and 
sulbactam sodium. After approximately 10 
days of treatment, the patient’s labs began to 
worsen showing: globulins 56 g/ L, leukocytes 
0.6 × 109/L, neutrophils 0 × 109/L, platelets 
20 × 109/L, hemoglobin 97 g/dL. On 
approximately day 17, the patient’s condition 
starting to improve with a noted decline in 
temperature, blood cultures with results of 
granulocytes > 1000, platelets > 50,000, bone 
marrow with increased nucleated cells and 
myeloid hyperplasia (Xiao, Li, You, Qian, Wei, 
2014). 
 Otterbein University, Westerville, Ohio  
Study showing the incidence of granulocytosis with two different 
types of antithyroid treatment. 
(Nakamura, H., Miyauchi, A., Miyawaki, N., Imagawa, J. Table 3). 
Conclusion 
Acute Medicine & Surgery identified 
and plan of treatment in hopes of 
minimizing the occurrence of adverse 
affects of anti-thyroid drug treatment.  
Some recommended methods include 
supportive care and identifying 
precipitating factors.  With the 
occurrence of agranulocytosis there is 
a possibility for fluid loss due to the 
occurrence of a fever and infections.  
Giving IV fluid is important to replace 
electrolytes and fluid volume loss.  As 
nurses and providers, it is important 
to monitor the patient’s intake and 
output in hopes of preventing a fluid 
deficit.   
Identifying precipitating factors can 
be done in a variety of methods. As 
previously stated, agranulocytosis 
occurs predominately in elderly 
females with the presentation of 
sepsis.  By monitoring temperature, 
heart rate, and blood pressure for 
acute changes, it will allow for 
prevention and early diagnosis.  Other 
diagnostic tests recommend including 
sputum cultures with complaints of a 
sore throat, and chest radiographs, as 
well as, monitoring the patients WBC 
with each visit (Idrose, 2015; Tajiti & 
Noguchi, 2005).  
Finally, as nurses we act as the last 
line of defense for our patient it is 
important to provide education.  By 
educating patients on anti-thyroid 
drug treatment, adverse affects, and 
precipitating signs and symptoms, we 
as a profession can continue to limit 
the number of patients experiencing 
agranulocytosis.  
Implications in 
Nursing Care 
Signs and symptoms of thyrotoxicosis 
requiring drug therapy, predisposing one to 
experiencing agranulocytosis, are often 
symptoms that one may experience on an 
every day basis.  Signs and symptoms 
include: thyroid eye syndrome, sweating, 
goiters, tremors, nervousness weight loss 
palpitations, however elderly patients will 
display minimal signs and symptoms.  Labs 
results will show an elevated FT4, FT3, and a 
suppressed TSH (Kobayashi, Noh, Mucosa, 
Kuna, Watanabe, et.al. 2014).                     
With the incidence of agranulocytosis being 
rare, education on the presenting signs and 
symptoms is often overlooked.        
Agranulocytosis most commonly occurs within 
the first few months of initiating treatment, 
with a higher frequency in female patients 
greater than 65 years of age (Nakamura, 
Miyauchi, Natsukp, Imagawa, 2013).  A 
patient that is experiencing agranulocytosis 
may remain asymptomatic with the only 
indicator being a low white blood cell count.  
However; individuals with presenting 
symptoms commonly include oropharyngeal 
infections, cervical lymphadenopathy, 
odynophagia, malaise, and an elevated 
temperature.  The appearance of 
agranulocytosis presents in the elderly as 
sepsis, skin infections, and pneumonia 
(Laurberg & Cooper, 2015).    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  
Signs and Symptoms 
As suggested in the case study, there is an 
instance in which bone marrow 
suppression can occur.  The suppression of 
bone marrow occurs in agranulocytosis 
with the development of pancytopenia.  
When pancytopenia occurs, studies suggest 
it is coupled with aplastic marrow, which 
affects only the granulocytes.  The 
granulocytes will the shift to the left, 
causing a decrease in mature cells.  This 
causes cytoplasmic swelling and 
irregularity in staining (Rosove, 1977).  
The underlying cause of agranulocytosis in 
antithryoid drug treatment has yet to be 
definitively pinpointed.  
Many theories suggest that the drug gains 
entry through the bone marrow where 
levels are to accumulate within the 
leukocytes exceeding the volume of 
plasma.  With leukocyte involvement, the 
utilization of glucose and oxygen is 
affected, showing a change in granulocytes 
and oxygen consumption. The higher level 
of the antithyroid affects the cellular level 
which extend through the erythroid cells.  
The leukocytes continue to be affected by 
antithyroid drug therapy, showing a 
decrease in the activity in nicotinamide 
adenine dinucleotide, granule bound 
nicotinamide adenine dinucleotide 
phosphate; therefore, decreasing the 
plasma membranes ability to fight off and 
engulf microorganisms (Rosove, 1977.) 
Underlying  
Pathophysiology 
The significance of the pathophysiology is 
important to practitioners and registered 
nurses because of the possibility of 
suppression of bone marrow and the 
ability of the antithyroid drug to engulf 
cells.  This limits one’s immune response 
and ability to fight off infection.  When a 
patient is prescribed treatment for 
hyperthyroidism, it is imperative to 
monitor for early signs of medication 
reaction.   If a fever, gingivitis, or sore 
throat develops, therapy should 
immediately be discontinued.  If symptoms 
are not identified at onset, opportunistic 
pathogens can enter the body leading 
further suppression of bone marrow and 
agranulocytosis, putting the patient at risk 
to become severely immunocompromised 
(Rovove, 1977.) 
We live in a culture that is busy and 
constantly on the go.  With little 
time to spare, often symptoms of an 
alteration in bodily function are 
pushed to the side and attribute to 
the stress of everyday life.  With 
symptoms including nausea, fatigue, 
weight loss, nervousness, and 
irritability, one may be more 
inclined to disregard these 
symptoms, only to attribute them to 
effects of a busy lifestyle.   
The presentation of the previously 
listed symptoms can formulate a 
medical diagnosis of 
hyperthyroidism.  According to the 
American Thyroid Association, 20 
million Americans will develop some 
type of alteration in thyroid function 
throughout their lifetime, and 60 
percent of those individuals will go 
undiagnosed. When a diagnosis is 
given, drug treatment options are 
limited. The two most common drug 
therapies include Propithiouracil 
and Methamazole (Rosove, 1977).   
Although drug therapies are 
beneficial in the treatment of 
hyperthyroidism, adverse affects 
from drug therapy can occur.  A 
more serious adverse affect of drug 
therapy would be Agranulocytosis.  
Agranulocytosis is condition in 
which the bone morrow is not 
producing adequate amounts of 
neutrophils.  With hyperthyroidism, 
the prescribed antithyroid drug 
therapy, suppresses the bodies 
ability to produce mature white 
blood cells, causing a drug-induced 
agranulocytosis.   
“Propylthiouracil and methimazole 
are used widely in the treatment of 
hyperthyroid disorders. The most 
important complication of the use of 
these drugs is depression of the 
neutrophilic granulocyte count.  
Granulocytopenia occurs in about 4 
percent and agranulocytosis occurs 
in about 0.3 percent of treated 
patients.  
Although this depression of the 
granulocyte count is reversible 
after the drug is discontinued, 
serious infection frequently 
accompanies agranulocytosis and 
accounts for almost al deaths 
related to the drugs (Rosove, 
1977).” 
 With such an abundant amount of 
Americans suffering from thyroid 
dysfunctions, it is important to 
provide ample education to 
patients on the adverse effects of 
antithyroid treatment, with the 
desire to prevent the development 
of agranulocytosis, as well as 
minimize their risk of infection 
from opportunistic pathogens. 
This particular topic sparks my 
interest due to my personal health.  
Two years ago, suddenly began 
feeling anxious, experiencing 
tremors, nauseated, and extreme 
fatigue.  I proceeded to disregard 
my body, only attribute these 
symptoms to the effects of being a 
night shift nurse, and not being 
able to always take a lunch break.  
I continued to disregard the 
symptoms, until one day I noticed 
my clothes began to fit more loosely 
and proceeded to experience a 40 
pound weight loss.  The extreme 
weight loss had occurred over a 50 
day period.  I immediately notified 
my primary care physician, 
numerous labs were drawn, 
eventually leading to the diagnosis 
of Graves’ disease. After being 
diagnosed with Graves’, I was 
prescribed 10 mg of methamazole 
three times daily. My doctor stated 
that if I began experiencing a sore 
throat to immediately notify the 
office and discontinue to the 
medication until further evaluation 
with no further explanation as to 
why the stated symptoms had any 
importance. I began researching 
immediately, only to find that, 
while uncommon, taking an 
antithyroid drug therapy could 
lead to dysfunction in the 
production of white blood cells, 
causing agranulocytosis.  
Significance in  
Pathophysiology 
